博雅生物(300294) - 2024年8月26日投资者关系活动记录表

Financial Performance - In the first half of 2024, the company achieved total revenue of 896 million CNY, with a net profit attributable to shareholders of 316 million CNY, and blood products revenue of 790 million CNY, reflecting a year-on-year growth of 3.64% [2] - The decline in consolidated revenue is primarily due to the transfer of Tianan Pharmaceutical and Fuda Pharmaceutical in the second half of 2023, which changed the scope of consolidation [2] - The company reported a collection volume of 246.89 tons from 14 operational plasma stations, marking a growth of 14.63% compared to the previous year [3] Strategic Expansion - The company acquired 100% of Green Cross Hong Kong Holdings, adding one production license and four operational plasma collection stations, expanding its presence into two new provincial regions [2] - The company is actively applying for new plasma stations in eligible areas, with four new county and city-level approvals obtained in the first half of the year [3] Product Development - The new product PCC and factor VIII have shown strong market performance, contributing positively to the company's profits [3] - The company is expected to launch the 10% immunoglobulin product next year, with a pricing strategy that will follow existing market products, potentially contributing 1.8 times the profit per ton of plasma compared to existing products [4] Cost and Profitability - The decline in gross margin is attributed to a less than 2% increase in plasma cost per ton, driven by higher blood plasma collection and screening costs, as well as increased production costs due to investments in smart factory construction [3] - The company plans to enhance production capacity and quality, with the smart factory project nearing completion, aiming to become a leading and efficient facility in the industry [5] Shareholder Returns - The company announced a cash dividend of 1.60 CNY (including tax) per 10 shares, based on a total of 504,248,738 shares [3] Future Outlook - The company is optimistic about the performance growth of the blood products sector in the second half of 2024, focusing on capacity expansion, quality improvement, and efficiency enhancement [5] - The strategic focus includes optimizing production capabilities and expanding the number of plasma stations, with a goal to achieve a balanced product structure among albumin, immunoglobulin, and factor products [5]